ELTROMBOPAG STADA 50mg tablets medication leaflet

B02BX05 eltrombopag • Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics

Eltrombopag is a medication used to treat thrombocytopenia, a condition characterized by a low platelet count in the blood. It is particularly indicated for patients with chronic idiopathic thrombocytopenic purpura or other conditions affecting platelet production.

This medication works by stimulating thrombopoietin receptors in the bone marrow, leading to increased platelet production. It is taken orally, usually once daily, as directed by a doctor.

Eltrombopag is generally well-tolerated but may cause side effects such as nausea, fatigue, headaches, or elevated liver enzymes. In rare cases, there may be an increased risk of blood clots.

It is important to strictly follow your doctor's recommendations and undergo regular blood tests to monitor the treatment's effects. Do not discontinue the medication without consulting a specialist.

General data about ELTROMBOPAG STADA 50mg

Substance: eltrombopag

Date of last drug list: 01-06-2025

Commercial code: W71074006

Concentration: 50mg

Pharmaceutical form: tablets

Quantity: 84

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: STADA ARZNEIMITTEL AG - GERMANIA

Holder: STADA ARZNEIMITTEL AG - GERMANIA

Number: 15977/2025/06

Shelf life: 30 months

Concentrations available for eltrombopag

12.5mg, 25mg, 50mg, 75mg